These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32087088)

  • 21. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases.
    Indra AK; Warot X; Brocard J; Bornert JM; Xiao JH; Chambon P; Metzger D
    Nucleic Acids Res; 1999 Nov; 27(22):4324-7. PubMed ID: 10536138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the
    Lesaffer B; Verboven E; Van Huffel L; Moya IM; van Grunsven LA; Leclercq IA; Lemaigre FP; Halder G
    Cells; 2019 Apr; 8(4):. PubMed ID: 31027317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Human CD68 Promoter-Driven Inducible Cre-Recombinase Mouse Line Allows Specific Targeting of Tissue Resident Macrophages.
    Rumianek AN; Davies B; Channon KM; Greaves DR; Purvis GSD
    Front Immunol; 2022; 13():918636. PubMed ID: 35874787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen-independent recombination in the RIP-CreER mouse.
    Liu Y; Suckale J; Masjkur J; Magro MG; Steffen A; Anastassiadis K; Solimena M
    PLoS One; 2010 Oct; 5(10):e13533. PubMed ID: 21063464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pax7 haploinsufficiency impairs muscle stem cell function in Cre-recombinase mice and underscores the importance of appropriate controls.
    Mademtzoglou D; Geara P; Mourikis P; Relaix F
    Stem Cell Res Ther; 2023 Oct; 14(1):294. PubMed ID: 37833800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temporal regulation of Cre-recombinase activity in Scl-positive neurons of the central nervous system.
    Bradley CK; Takano EA; Göthert JR; Göttgens B; Green AR; Begley CG; van Eekelen JA
    Genesis; 2007 Mar; 45(3):145-51. PubMed ID: 17330263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysregulation of humoral immunity in Foxp3 conditional-knockout mice.
    Tai Y; Sakamoto K; Takano A; Haga K; Harada Y
    Biochem Biophys Res Commun; 2019 Jun; 513(4):787-793. PubMed ID: 31000202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perinatal induction of Cre recombination with tamoxifen.
    Lizen B; Claus M; Jeannotte L; Rijli FM; Gofflot F
    Transgenic Res; 2015 Dec; 24(6):1065-77. PubMed ID: 26395370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of endothelial promoter efficiency and specificity in mice reveals a subset of Pdgfb-positive hematopoietic cells.
    Kilani B; Gourdou-Latyszenok V; Guy A; Bats ML; Peghaire C; Parrens M; Renault MA; Duplàa C; Villeval JL; Rautou PE; Couffinhal T; James C
    J Thromb Haemost; 2019 May; 17(5):827-840. PubMed ID: 30801958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tamoxifen-inducible Cre-recombination in articular chondrocytes of adult Col2a1-CreER(T2) transgenic mice.
    Zhu M; Chen M; Lichtler AC; O'Keefe RJ; Chen D
    Osteoarthritis Cartilage; 2008 Jan; 16(1):129-30. PubMed ID: 17888690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Cre recombinase transgene with mosaic, widespread tamoxifen-inducible action.
    Guo C; Yang W; Lobe CG
    Genesis; 2002 Jan; 32(1):8-18. PubMed ID: 11835669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues.
    Hameyer D; Loonstra A; Eshkind L; Schmitt S; Antunes C; Groen A; Bindels E; Jonkers J; Krimpenfort P; Meuwissen R; Rijswijk L; Bex A; Berns A; Bockamp E
    Physiol Genomics; 2007 Sep; 31(1):32-41. PubMed ID: 17456738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inducible Cre mice.
    Feil S; Valtcheva N; Feil R
    Methods Mol Biol; 2009; 530():343-63. PubMed ID: 19266339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying the variables that drive tamoxifen-independent CreERT2 recombination: Implications for microglial fate mapping and gene deletions.
    Van Hove H; Antunes ARP; De Vlaminck K; Scheyltjens I; Van Ginderachter JA; Movahedi K
    Eur J Immunol; 2020 Mar; 50(3):459-463. PubMed ID: 31785096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamoxifen-inducible Cre-mediated recombination in adipocytes.
    Sassmann A; Offermanns S; Wettschureck N
    Genesis; 2010 Oct; 48(10):618-25. PubMed ID: 20715175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outer hair cell-specific prestin-CreERT2 knockin mouse lines.
    Fang J; Zhang WC; Yamashita T; Gao J; Zhu MS; Zuo J
    Genesis; 2012 Feb; 50(2):124-31. PubMed ID: 21954035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Split-CreERT2: temporal control of DNA recombination mediated by split-Cre protein fragment complementation.
    Hirrlinger J; Requardt RP; Winkler U; Wilhelm F; Schulze C; Hirrlinger PG
    PLoS One; 2009 Dec; 4(12):e8354. PubMed ID: 20016782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation of aggrecan-CreERT2 knockin mice for inducible Cre activity in adult cartilage.
    Henry SP; Jang CW; Deng JM; Zhang Z; Behringer RR; de Crombrugghe B
    Genesis; 2009 Dec; 47(12):805-14. PubMed ID: 19830818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refinement of inducible gene deletion in embryos of pregnant mice.
    Savery D; Maniou E; Culshaw LH; Greene NDE; Copp AJ; Galea GL
    Birth Defects Res; 2020 Jan; 112(2):196-204. PubMed ID: 31793758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inducible Cre/loxP recombination in the mouse proximal tubule.
    Dworniczak B; Skryabin B; Tchinda J; Heuck S; Seesing FJ; Metzger D; Chambon P; Horst J; Pennekamp P
    Nephron Exp Nephrol; 2007; 106(1):e11-20. PubMed ID: 17356303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.